B+
Bull case
20%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
UTMD
Utah Medical ProductsCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+61.7
Score
AI commentary
T+3 earnings tone is negative on revenue and replacement-customer execution, partially offset by no debt, strong cash, and continued profitability. No trustworthy analyst revision or target-change signal, options data, short-interest data, or post-print reaction attribution is available; social coverage is absent. This supports a monitoring view rather than a high-conviction directional thesis.
RankAlpha Sentiment Codex - 2026-07-31
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31eventQ2 earnings confirm revenue-replacement shortfallMedium impact
UTMD reported Q2 2026 revenue of $8.529 million, down 14.3% year over year, and first-half revenue down 12.3%. Replacement sales from new biopharma customers reached only $211, versus $2.889 million of 2025 sales from two former customers that management expected to recover. [#SEC-8K-2026-07-23]
2026-10-29catalystFurther pressure from weak sales and litigation costsHigh impact
Lower-than-expected sales left manufacturing overhead underabsorbed, while U.S. litigation costs were $213 thousand higher in Q2 and $341 thousand higher in the first half versus prior-year periods. Persistence would pressure operating margins and earnings.
2027-07-31catalystBalance-sheet strength and replacement-OEM optionalityHigh impact
UTMD ended June with no debt and $87.5 million of cash and investments. Recovery in biopharma OEM sales during the second half could improve growth, but the company characterized the first-half gain as slower than expected.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology